Asset profile
AR1001
Small molecule
Evidence outlook · registrational
Alzheimer's Disease: registrational readout pending
Entered Phase 3 on partial signal mid-stage evidence. No upcoming registrational readout date is posted to the registry — check News for topline announcements.
NCT03625622: The study was randomized, quadruple-masked, and placebo-controlled, with 210 participants, and used clinical cognitive and global-change measures (ADAS-Cog 13 and ADCS-CGIC) as primary endpoints. However, no outcome results or statistical comparisons are posted, so the primary endpoint cannot be determined to have been met.
The overall-population primary endpoint showed no significant differences (published qualitatively); the numeric improvement shown is a post-hoc monotherapy subgroup analysis.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.